Roman Graf
@romangraf.bsky.social
Reposted by Roman Graf
Out now: We present antibody-lectin chimeras (AbLecs) as a molecular platform to target sugars, or glycans, for cancer immunotherapy.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
@mitkochinstitute.bsky.social @mitdeptofbe.bsky.social @mitcheme.bsky.social @stanford-chemh.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
@mitkochinstitute.bsky.social @mitdeptofbe.bsky.social @mitcheme.bsky.social @stanford-chemh.bsky.social
Antibody-lectin chimeras for glyco-immune checkpoint blockade - Nature Biotechnology
Cancer immunotherapy benefits from antibody-lectin chimeras that block glyco-immune checkpoints.
www.nature.com
December 16, 2025 at 3:01 PM
Out now: We present antibody-lectin chimeras (AbLecs) as a molecular platform to target sugars, or glycans, for cancer immunotherapy.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
@mitkochinstitute.bsky.social @mitdeptofbe.bsky.social @mitcheme.bsky.social @stanford-chemh.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
@mitkochinstitute.bsky.social @mitdeptofbe.bsky.social @mitcheme.bsky.social @stanford-chemh.bsky.social
Reposted by Roman Graf
Elucidating lipid nanoparticle properties and structure through biophysical analyses - @guptapenn.bsky.social
@pennengineering.bsky.social @pennmedicine.bsky.social go.nature.com/4oTt639
@pennengineering.bsky.social @pennmedicine.bsky.social go.nature.com/4oTt639
Elucidating lipid nanoparticle properties and structure through biophysical analyses - Nature Biotechnology
Guidance for optimizing lipid nanoparticle formulations is derived using sophisticated biophysical techniques.
go.nature.com
October 23, 2025 at 4:24 PM
Elucidating lipid nanoparticle properties and structure through biophysical analyses - @guptapenn.bsky.social
@pennengineering.bsky.social @pennmedicine.bsky.social go.nature.com/4oTt639
@pennengineering.bsky.social @pennmedicine.bsky.social go.nature.com/4oTt639
Reposted by Roman Graf
Jennifer Doudna's latest startup, Azalea Therapeutics, launched with $82M. It's based on virus like particles developed by CEO Jenny Hamilton and a new CAR-T trick developed by UCSF's Justin Eyquem. Their goal? The ultimate CRISPR-based in vivo CAR-T. @endpts.com - endpoints.news/jennifer-dou...
Jennifer Doudna startup launches with $82M to apply new CRISPR delivery technology to in vivo CAR-T
Nobel laureate Jennifer Doudna's Azalea Therapeutics raises $82M to develop new CRISPR delivery system for in vivo CAR-T cell therapies targeting blood cancers.
endpoints.news
November 4, 2025 at 1:37 PM
Jennifer Doudna's latest startup, Azalea Therapeutics, launched with $82M. It's based on virus like particles developed by CEO Jenny Hamilton and a new CAR-T trick developed by UCSF's Justin Eyquem. Their goal? The ultimate CRISPR-based in vivo CAR-T. @endpts.com - endpoints.news/jennifer-dou...
Reposted by Roman Graf
💡 This article offers a #computational method to create #synthetic receptors that help engineered T cells respond more effectively to #tumors.
Read the paper published by J. A. Rath et al., in @natbiomedeng.nature.com
🔗 www.nature.com/articles/s41...
Read the paper published by J. A. Rath et al., in @natbiomedeng.nature.com
🔗 www.nature.com/articles/s41...
Computational design of synthetic receptors with programmable signalling activity for enhanced cancer T cell therapy - Nature Biomedical Engineering
A computational method designs receptors called T-SenSERs, which have predictable signalling responses to tumour microenvironment soluble factors and can be co-expressed with conventional CARs in T ce...
www.nature.com
October 30, 2025 at 9:17 AM
💡 This article offers a #computational method to create #synthetic receptors that help engineered T cells respond more effectively to #tumors.
Read the paper published by J. A. Rath et al., in @natbiomedeng.nature.com
🔗 www.nature.com/articles/s41...
Read the paper published by J. A. Rath et al., in @natbiomedeng.nature.com
🔗 www.nature.com/articles/s41...
Reposted by Roman Graf
Integrated epigenetic and genetic programming of primary human T cells - @gladstoneinst.bsky.social @ucsanfrancisco.bsky.social @j-eyquem.bsky.social @marsonlab.bsky.social go.nature.com/3WOJJAJ
Integrated epigenetic and genetic programming of primary human T cells - Nature Biotechnology
Multiplexed editing in primary human T cells generates enhanced immune cell therapies.
go.nature.com
October 21, 2025 at 3:57 PM
Integrated epigenetic and genetic programming of primary human T cells - @gladstoneinst.bsky.social @ucsanfrancisco.bsky.social @j-eyquem.bsky.social @marsonlab.bsky.social go.nature.com/3WOJJAJ
Reposted by Roman Graf
For readers interested in finding out more about in vivo CAR-T therapies such as those at the centre of the $1.5 billion acquisition of Orbital Therapeutics by Bristol Myers Squibb today, here's a comprehensive review
rdcu.be/eKnwV
nature.com/articles/s41...
rdcu.be/eKnwV
nature.com/articles/s41...
In vivo chimeric antigen receptor (CAR)-T cell therapy - Nature Reviews Drug Discovery
In vivo chimeric antigen receptor (CAR)-T cell engineering uses targeted delivery systems to generate CAR-T cells directly in patients, bypassing ex vivo manufacturing. This Review examines emerging viral and lipid nanoparticle platforms, early clinical proof of concept and potential applications beyond cancer.
nature.com
October 10, 2025 at 1:35 PM
For readers interested in finding out more about in vivo CAR-T therapies such as those at the centre of the $1.5 billion acquisition of Orbital Therapeutics by Bristol Myers Squibb today, here's a comprehensive review
rdcu.be/eKnwV
nature.com/articles/s41...
rdcu.be/eKnwV
nature.com/articles/s41...
Reposted by Roman Graf
CAR T cells showcase the enormous potential of cell therapies, but often fail due to lack of evolutionary optimization. Today in @nature.com , we use #CELLFIE to engineer cell therapies at scale and share the largest resource of CRISPR screens in CAR T cells. www.nature.com/articles/s41...
Systematic discovery of CRISPR-boosted CAR T cell immunotherapies - Nature
CELLFIE, a CRISPR platform for optimizing cell-based immunotherapies, identifies gene knockouts that enhance CAR T cell efficacy using in vitro and in vivo screens.
www.nature.com
September 24, 2025 at 3:44 PM
CAR T cells showcase the enormous potential of cell therapies, but often fail due to lack of evolutionary optimization. Today in @nature.com , we use #CELLFIE to engineer cell therapies at scale and share the largest resource of CRISPR screens in CAR T cells. www.nature.com/articles/s41...
Reposted by Roman Graf
📢 New in #Nature!
Researchers led by Dr. Chris at Stanford have leveraged synthetic #CytokineReceptor engineering to successfully rewire #TCell fate decisions and amplify anti-cancer immunity.
📗: https://go.nature.com/4n6F6gQ
🔊: https://bit.ly/4mYJIWy
Researchers led by Dr. Chris at Stanford have leveraged synthetic #CytokineReceptor engineering to successfully rewire #TCell fate decisions and amplify anti-cancer immunity.
📗: https://go.nature.com/4n6F6gQ
🔊: https://bit.ly/4mYJIWy
September 15, 2025 at 2:32 PM
📢 New in #Nature!
Researchers led by Dr. Chris at Stanford have leveraged synthetic #CytokineReceptor engineering to successfully rewire #TCell fate decisions and amplify anti-cancer immunity.
📗: https://go.nature.com/4n6F6gQ
🔊: https://bit.ly/4mYJIWy
Researchers led by Dr. Chris at Stanford have leveraged synthetic #CytokineReceptor engineering to successfully rewire #TCell fate decisions and amplify anti-cancer immunity.
📗: https://go.nature.com/4n6F6gQ
🔊: https://bit.ly/4mYJIWy
Reposted by Roman Graf
A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2 go.nature.com/4mTBGhr
A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2 - Nature Biotechnology
A screen for protein degraders discovers hits by imaging cell survival.
go.nature.com
September 10, 2025 at 4:17 PM
A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2 go.nature.com/4mTBGhr
Reposted by Roman Graf
Exciting to see our protein binder design pipeline BindCraft published in its final form in @Nature ! This has been an amazing collaborative effort with Lennart, Christian, @sokrypton.org, Bruno and many other amazing lab members and collaborators.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
August 27, 2025 at 4:14 PM
Exciting to see our protein binder design pipeline BindCraft published in its final form in @Nature ! This has been an amazing collaborative effort with Lennart, Christian, @sokrypton.org, Bruno and many other amazing lab members and collaborators.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Roman Graf
Targeted delivery of diverse biomolecules with engineered bacterial nanosyringes - @zhangf.bsky.social go.nature.com/46OFcoj
Targeted delivery of diverse biomolecules with engineered bacterial nanosyringes - Nature Biotechnology
Ribonucleoproteins, nucleic acids and proteins are delivered into target cell types with nanosyringes.
go.nature.com
August 12, 2025 at 2:54 PM
Targeted delivery of diverse biomolecules with engineered bacterial nanosyringes - @zhangf.bsky.social go.nature.com/46OFcoj
Reposted by Roman Graf
PANCS-Binders (phage-assisted noncontinuous selection of protein binders) screens multiple high-diversity protein libraries against a panel of dozens of targets for high-throughput binder discovery. @chembiobryan.bsky.social @mstyles-chembiol.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
August 6, 2025 at 7:49 PM
PANCS-Binders (phage-assisted noncontinuous selection of protein binders) screens multiple high-diversity protein libraries against a panel of dozens of targets for high-throughput binder discovery. @chembiobryan.bsky.social @mstyles-chembiol.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Roman Graf
Nature research paper: Design of highly functional genome editors by modelling CRISPR–Cas sequences
go.nature.com/3UAYBBB
go.nature.com/3UAYBBB
Design of highly functional genome editors by modelling CRISPR–Cas sequences - Nature
Gene editors designed using artificial intelligence can undertake precision editing of the human genome.
go.nature.com
July 30, 2025 at 6:50 PM
Nature research paper: Design of highly functional genome editors by modelling CRISPR–Cas sequences
go.nature.com/3UAYBBB
go.nature.com/3UAYBBB
Reposted by Roman Graf
🍹Sharma, Jiao et al. report glycosylation of small RNAs within #exosomes and propose a glycosylation-dependent mechanism for #RNA targeting into exosomes, which may influence intercellular communication and RNA stability in the extracellular environment.
👉https://rdcu.be/eykKY
bit.ly/455vyuP
👉https://rdcu.be/eykKY
bit.ly/455vyuP
Extracellular exosomal RNAs are glyco-modified - Nature Cell Biology
Sharma, Jiao and colleagues report glycosylation of small RNAs within exosomes and propose a glycosylation-dependent mechanism for RNA targeting into exosomes, which may influence intercellular commun...
bit.ly
July 29, 2025 at 12:07 PM
🍹Sharma, Jiao et al. report glycosylation of small RNAs within #exosomes and propose a glycosylation-dependent mechanism for #RNA targeting into exosomes, which may influence intercellular communication and RNA stability in the extracellular environment.
👉https://rdcu.be/eykKY
bit.ly/455vyuP
👉https://rdcu.be/eykKY
bit.ly/455vyuP
Reposted by Roman Graf
I am super excited to announce that I will be starting my lab at the Department of Pharmacology of the University of Zurich in Switzerland next year!
July 25, 2025 at 7:48 AM
I am super excited to announce that I will be starting my lab at the Department of Pharmacology of the University of Zurich in Switzerland next year!
Reposted by Roman Graf
An alternative receptor enhances AAV transduction in vivo, offering the potential to reduce dose-related toxicities while maintaining efficacy in AAV-mediated gene therapy. www.cell.com/cell/fulltex... #NBThighlight
An alternate receptor for adeno-associated viruses
Dhungel et al. report an alternate receptor for AAV (AAVR2, carboxypeptidase D), which
is distinct from the multi-serotype AAV receptor (AAVR). This study provides insights
into AAV biology and clinic...
www.cell.com
July 16, 2025 at 7:51 AM
An alternative receptor enhances AAV transduction in vivo, offering the potential to reduce dose-related toxicities while maintaining efficacy in AAV-mediated gene therapy. www.cell.com/cell/fulltex... #NBThighlight
Reposted by Roman Graf
Nature research paper: Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery
https://go.nature.com/3TRMdNd
https://go.nature.com/3TRMdNd
Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery - Nature
A CRISPR knock-in strategy that uses endogenous gene regulatory mechanisms can engineer ‘armoured’ CAR T cells that secrete proinflammatory cytokines directly within a tumour without causing toxicity, leading to prolonged survival in mice.
go.nature.com
July 4, 2025 at 5:33 PM
Nature research paper: Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery
https://go.nature.com/3TRMdNd
https://go.nature.com/3TRMdNd
Reposted by Roman Graf
Reposted by Roman Graf
CD8-targeted lipid nanoparticles carrying anti-CD19 CAR mRNA were developed to generate CAR-T cells directly in vivo, demonstrating effective B cell depletion for potential treatment of B cell malignancies and autoimmune diseases. www.science.org/doi/10.1126/... #NBThighlight
In vivo CAR T cell generation to treat cancer and autoimmune disease
Chimeric antigen receptor (CAR) T cell therapies have transformed treatment of B cell malignancies. However, their broader application is limited by complex manufacturing processes and the necessity f...
www.science.org
June 20, 2025 at 7:01 AM
CD8-targeted lipid nanoparticles carrying anti-CD19 CAR mRNA were developed to generate CAR-T cells directly in vivo, demonstrating effective B cell depletion for potential treatment of B cell malignancies and autoimmune diseases. www.science.org/doi/10.1126/... #NBThighlight
Reposted by Roman Graf
Excited to unveil Boltz-2, our new model capable not only of predicting structures but also binding affinities! Boltz-2 is the first AI model to approach the performance of FEP simulations while being more than 1000x faster! All open-sourced under MIT license! A thread… 🤗🚀
June 6, 2025 at 1:46 PM
Excited to unveil Boltz-2, our new model capable not only of predicting structures but also binding affinities! Boltz-2 is the first AI model to approach the performance of FEP simulations while being more than 1000x faster! All open-sourced under MIT license! A thread… 🤗🚀
Reposted by Roman Graf
Synthetic biology could enable new types of programmable therapeutics. Our new preprint introduces synthetic protein circuits that selectively trigger cell death in Ras-mutant cancer cells, with interesting advantages compared to existing approaches.
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
www.biorxiv.org
June 3, 2025 at 12:11 AM
Synthetic biology could enable new types of programmable therapeutics. Our new preprint introduces synthetic protein circuits that selectively trigger cell death in Ras-mutant cancer cells, with interesting advantages compared to existing approaches.
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Reposted by Roman Graf
The gene editing tool STITCHR contains an R2 retrotransposon fused to a CRISPR–Cas9 nickase to install diverse edits, including multi-kilobase insertions, in vitro. www.nature.com/articles/s41... #NBTHighlight
Reprogramming site-specific retrotransposon activity to new DNA sites - Nature
A study of retrotransposon activity repurposes a retroelement called R2Tocc to create a programmable system called STITCHR that enables diverse genome edits including efficient, scarless large pa...
www.nature.com
April 14, 2025 at 9:01 AM
The gene editing tool STITCHR contains an R2 retrotransposon fused to a CRISPR–Cas9 nickase to install diverse edits, including multi-kilobase insertions, in vitro. www.nature.com/articles/s41... #NBTHighlight
Reposted by Roman Graf
Evolution-guided protein design of IscB for persistent epigenome editing in vivo - @zhangf.bsky.social @broadinstitute.org @hhmi.org go.nature.com/44XVBph
Evolution-guided protein design of IscB for persistent epigenome editing in vivo - Nature Biotechnology
A combination of engineering approaches is used to improve the function of IscB for a variety of editing activities in vivo.
go.nature.com
May 7, 2025 at 1:47 PM
Evolution-guided protein design of IscB for persistent epigenome editing in vivo - @zhangf.bsky.social @broadinstitute.org @hhmi.org go.nature.com/44XVBph
Reposted by Roman Graf
1/10 Today in @science.org in collaboration with
the Liu group we report the development of a laboratory-evolved CRISPR-associated transposase (evoCAST) that supports therapeutically relevant levels of RNA-programmable gene insertion in human cells. drive.google.com/file/d/1I-Ub...
the Liu group we report the development of a laboratory-evolved CRISPR-associated transposase (evoCAST) that supports therapeutically relevant levels of RNA-programmable gene insertion in human cells. drive.google.com/file/d/1I-Ub...
May 15, 2025 at 10:49 PM
1/10 Today in @science.org in collaboration with
the Liu group we report the development of a laboratory-evolved CRISPR-associated transposase (evoCAST) that supports therapeutically relevant levels of RNA-programmable gene insertion in human cells. drive.google.com/file/d/1I-Ub...
the Liu group we report the development of a laboratory-evolved CRISPR-associated transposase (evoCAST) that supports therapeutically relevant levels of RNA-programmable gene insertion in human cells. drive.google.com/file/d/1I-Ub...
Reposted by Roman Graf
Self-assembling protein nanoparticles for cytosolic delivery of nucleic acids and proteins - @bidmcreseach.bsky.social go.nature.com/4mxazJw
Self-assembling protein nanoparticles for cytosolic delivery of nucleic acids and proteins - Nature Biotechnology
Biomacromolecules are delivered into cells using nanoparticles made of elastin and endosomal escape sequences.
go.nature.com
May 15, 2025 at 5:10 PM
Self-assembling protein nanoparticles for cytosolic delivery of nucleic acids and proteins - @bidmcreseach.bsky.social go.nature.com/4mxazJw